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Serine proteases (SPs) are typically synthesized as precursors, termed proenzymes 
or zymogens, and the fully active form is produced via limited proteolysis by another 
protease or by autoactivation. The lectin pathway of the complement system is 
initiated by mannose-binding lectin (MBL)-associated SPs (MASP)-1, and MASP-2, 
which are known to be present as proenzymes in blood. The third SP of the lectin 
pathway, MASP-3, was recently shown to be the major activator, and the exclusive 
“resting blood” activator of profactor D, producing factor D, the initiator protease of 
the alternative pathway. Because only activated MASP-3 is capable of carrying out this 
cleavage, it was presumed that a significant fraction of MASP-3 must be present in the 
active form in resting blood. Here, we aimed to detect active MASP-3 in the blood by 
a more direct technique and to quantitate the active to zymogen ratio. First, MASPs 
were partially purified (enriched) from human plasma samples by affinity chromatography 
using immobilized MBL in the presence of inhibitors. Using this MASP pool, only the 
zymogen form of MASP-1 was detected by Western blot, whereas over 70% MASP-3 
was in an activated form in the same samples. Furthermore, the active to zymogen ratio 
of MASP-3 showed little individual variation. It is enigmatic how MASP-3, which is not 
able to autoactivate, is present mostly as an active enzyme, whereas MASP-1, which 
has a potent autoactivation capability, is predominantly proenzymic in resting blood. In 
an attempt to explain this phenomenon, we modeled the basal level fluid-phase activa-
tion of lectin pathway proteases and their subsequent inactivation by C1 inhibitor and 
antithrombin using available and newly determined kinetic constants. The model can 
explain extensive MASP-3 activation only if we assume efficient intracomplex activation 
of MASP-3 by zymogen MASP-1. On the other hand, the model is in good agreement 
with the fact that MASP-1 and -2 are predominantly proenzymic and some of them is 
present in the form of inactive serpin–protease complexes. As an alternative hypothesis, 
MASP-3 activation by proprotein convertases is also discussed.
Keywords: innate immunity, complement, lectin pathway, serine protease, proenzyme, autoactivation, reaction 
kinetics
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inTrODUcTiOn
The complement system, as an essential part of the innate 
immune response, eliminates invading microorganisms and 
dangerous host cells (1, 2). The complement cascade is composed 
of more than 30 proteins. Key components of the system are ser-
ine proteases (SPs), which typically circulate in bloodstream in 
the zymogen form until their successive cleavage and activation 
(3). Complement activation can be triggered via three different, 
however interconnected routes: the classical, lectin, and alterna-
tive pathways, then the three routes converge into the common 
terminal pathway. When the classical or lectin pathways are acti-
vated, it results in the formation of the C3 convertase, C4bC2a, 
composed of the cleaved forms of complement factors C4 and C2 
(4). The alternative pathway serves as an amplification loop, but it 
can also be activated on its own by the “tick-over” mechanism (5).
Activation of the lectin pathway is initiated on surfaces dis-
playing various arrays of carbohydrates or acetyl groups, which 
can be recognized by (at least) five different pattern recognition 
molecules (PRMs): mannose-binding lectin (MBL), H-ficolin 
(ficolin-3), L-ficolin (ficolin-2), M-ficolin (ficolin-1), and CL-LK 
(a heterocomplex of collectin liver 1 and collectin kidney 1) 
(6–8). The recognition of dangerous patterns is transformed to 
enzymatic signals by two proteases complexed with the PRMs, 
MBL-associated SP 1 and 2 (MASP-1, MASP-2). The first proteo-
lytic step is the autoactivation of MASP-1, which then activates 
MASP-2. Both enzymes can cleave C2, however C4 is cleaved 
only by MASP-2. As a consequence both MASP-1 and MASP-2 
play essential roles in the formation of the C4bC2a enzymatic 
complex (9–11).
All MASPs have the same six-domain structure (4, 7). The 
C-terminal SP domain is preceded by five regulatory domains 
in the order of CUB1-EGF-CUB2-CCP1-CCP2. CUB stands for 
C1r/C1s, sea urchin Uegf and bone morphogenetic protein-1 
domain, EGF for epidermal growth factor domain, and CCP for 
complement control protein domain. Upon activation an Arg-Ile 
(R-I) bond is cleaved within the SP domain and the resulting two 
chains, termed A and B, are held together by a disulfide bridge.
Mannose-binding lectin-associated SP-1 has relatively broad 
substrate specificity (12), as a result it is involved in coagulation 
(13) and certain proinflammatory reactions, e.g., cleavage of 
PAR receptors on endothelial cells results in their activation, and 
cleavage of high molecular weight kininogen produces the proin-
flammatory bradykinin (4, 14, 15). The role of two non-catalytic 
associated proteins (MAp19 or sMAP, MAp44, or MAP1) is 
less clear (16–19). The third SP of the lectin pathway, MASP-3 
(20), along with MAp19 and MAp44 were initially considered 
simply as negative lectin pathway regulators, but recent results 
implicated that MASP-3 has an important role in the activation 
of the complement system in connection with the alternative 
pathway (21–25).
Factor D (FD), a single-domain SP, is a key enzyme for the 
alternative pathway. FD has only one natural substrate, factor B 
(FB) complexed with C3b (26). Until recently, it was believed that 
FD is activated at the site of the synthesis, maybe even before 
secretion (27), because only active FD could be purified from 
normal blood (28, 29). Although in mammalian cell cultures pre-
dominantly active FD was detected (30, 31), the zymogen form 
was also present (31). In insect cells, proenzyme FD (pro-FD) is 
expressed almost exclusively (22, 32). Recent results by Pihl et al. 
(25) and personal discussions with Elod Kortvely (unpublished 
data) suggest that both FD and pro-FD are present in normal 
human blood with FD being the dominant form.
A link between early complement pathways was proposed by 
Takahashi et al. observing the lack of alternative pathway activity 
in MASP1 knock-out mice. Due to the fact that MASP-1 and 
MASP-3 are two splice variants from the same gene such mice 
lacks both proteins. In the absence of both MASP-1 and MASP-3 
only zymogen FD was detected. At first, MASP-1 was suggested 
to be responsible for pro-FD activation, although supplementing 
the serum from such mice with recombinant MASP-1 did not 
restore the alternative pathway (33). Later, MASP-3 was also 
implicated as an enzyme capable of converting pro-FD to active 
FD, and even proenzyme MASP-3 was proposed to be able to 
carry out such cleavage (21). Subsequent results questioned the 
involvement of MASP-1 and/or MASP-3 in alternative pathway 
activation. In the serum of a MASP-1/3-deficient patient, suffer-
ing from the Malpuech–Michels–Mingarelli–Carnevale (3MC) 
syndrome causing serious craniofacial defects, functional 
alternative pathway activity was observed (10). Nevertheless 
a following discussion revealed that mainly pro-FD can be 
detected in the blood of these 3MC patients (34). Furthermore, 
uncontrolled alternative pathway activity was observed in 
MASP-1/3 and factor H codeficient mice just like in knock-out 
mice deficient for factor H only (35). These data contradicted the 
view that MASP-1 and/or MASP-3 is involved in the function of 
the alternative pathway, and the exact way of pro-FD conversion 
remained unclear.
Our previous studies clarified this controversy and the role 
of MASPs in pro-FD activation. First, we determined the rate 
constants of pro-FD cleavage for all three MASPs. We found 
that only the active forms of MASPs are able to convert pro-FD 
to FD. Next, using fluorescently labeled recombinant pro-FD, 
we detected the activation of this exogenous pro-FD in human 
blood samples. With our previously developed MASP-1- and 
MASP-2-specific inhibitors we ruled out MASP-1 and MASP-2 
as potential pro-FD activators in resting blood (22). Then, 
using a MASP-3-specific inhibitor, we showed that MASP-3 is 
the major activator of pro-FD in general, and it is the exclusive 
pro-FD activator under resting conditions in human blood (23). 
By “resting” conditions, we mean that neither the complement 
nor the coagulation system is activated above the basal level. 
Furthermore, our results supported thrombin and/or another 
coagulation protease serving as a potential backup enzyme for 
this conversion in coagulated blood (i.e., human serum) (22, 23). 
Our findings also imply that under resting conditions, at least 
Abbreviations: MBL, mannose-binding lectin; MASP, MBL-associated serine 
protease; cf, catalytic fragment; MAp, MBL-associated protein; PRM, pattern 
recognition molecule; CL, collectin; SP, serine protease; CUB, C1r/C1s, sea urchin 
Uegf and bone morphogenetic protein-1; EGF, epidermal growth factor; CCP, 
complement control protein; FD, factor D; pro-FD, proenzyme factor D; AP, 
alkaline phosphatase; 3MC, Malpuech–Michels–Mingarelli–Carnevale; NPGB, 
4-nitrophenyl 4′-guanidinobenzoate.
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a fraction of MASP-3 must be present in the active form in the 
bloodstream (22, 23). The average serum or plasma concentration 
of MASP-3 was published in several studies as about 5–7 µg/ml 
(36–39), however, the extent of MASP-3 activation has remained 
unknown.
In this study, we aimed to determine the active to zymogen 
MASP-3 ratio in normal resting human blood. In order to 
minimize activation during sample preparation, we used EDTA 
plasma (pooled or individual) as starting material, then MASPs 
were purified on MBL-Sepharose in the presence of broad speci-
ficity inhibitors, Pefabloc and 4-nitrophenyl 4′-guanidinobenzo-
ate (NPGB). MASPs were then detected by Western blotting. 
Our data imply that MASP-3 circulates mostly in the active form 
in human blood. Of course the question arises how MASP-3 is 
activated, especially in the light of the fact that MASP-3, unlike 
MASP-1, cannot autoactivate. In an attempt to explain the 
observed facts, a kinetic model of lectin pathway activation was 
set up, which, using reasonable assumptions, provides a solution 
for the phenomenon.
MaTerials anD MeThODs
Proteins, reagents, Blood samples,  
and antibodies
Active recombinant MASP-1 and MASP-2 catalytic fragments 
(MASP-1cf, MASP-2cf), encompassing the complement control 
protein domains 1 and 2 and the SP domain (CCP1-CCP2-SP), 
were produced as described (11, 40, 41). Stable zymogen mutant 
forms MASP-1cf (R448Q) and MASP-2cf (R444Q) were prepared 
as described (11, 42). Zymogen MASP-3cf (also the CCP1-
CCP2-SP region) was produced and then further purified as 
described (11, 22). Activated MASP-3cf was prepared from zymo-
gen MASP-3cf, and then further purified as described (22, 43). 
Pro-FD was produced in insect cells and then it was activated as 
described (22). CNBr-Activated Sepharose 4 Fast Flow resin was 
purchased from GE Healthcare. Recombinant human mannan-
binding lectin (rMBL), produced based on the protocol of Vorup-
Jensen et al. (44), was from Enzon Pharmaceuticals.
Blood was drawn from ten healthy volunteers into 
S-Monovette K3E EDTA tubes (Sarstedt) to produce fresh 
pooled plasma. After centrifugation, samples were combined, 
and kept at −70°C in aliquots. Blood was drawn from seven 
healthy volunteers into S-Monovette K3E EDTA tubes 
(Sarstedt) to produce fresh individual plasma samples. After 
centrifugation, samples were kept at −70°C in aliquots. The 
study was conducted in conformity with the WMA Declaration 
of Helsinki. Experimental protocols were approved by the local 
ethics committee (permission number: TUKEB 9190-1/2017/
EKU). Informed consent was obtained for the isolation of 
peripheral venous blood from the donors.
Pefabloc SC was purchased from Sigma-Aldrich (Fluka 
brand). NPGB was purchased from Merck. Monoclonal anti-
body against human complement MASP-3 catalytic domain 
was purchased from RD Systems (catalog number: MAB1724). 
Anti-Mouse IgG alkaline phosphatase antibody (catalog num-
ber A2429), 4-nitro blue tetrazolium chloride (NBT), and the 
5-bromo-4-chloro-3-indolyl phosphate disodium salt (BCIP) 
were purchased from Sigma-Aldrich. The Precision Plus Protein 
Kaleidoscope Prestained Standard was from Bio-Rad, the LMW-
SDS Marker was from GE Healthcare.
MasP-1-sP, anti-MasP-1-sP Polyclonal 
antibody, and its alkaline Phosphatase 
conjugate
The MASP-1-SP (MASP-1 SP domain) gene was amplified 
from the MASP-1cf construct (41). The forward primer 
(5′-GGCCGCTAGCATGACTGTGTGTGGGCTCCCCA 
AG-3′) contained an expression enhancing sequence (Ala-
Ser-Met-Thr, underlined) and a NheI restriction site (bold and 
italic), while the reverse primer (5′-CGGAATTCTCAGTT 
CCTCACTCCGGT-3′) contained an EcoRI restriction site (bold 
and italic). The NheI-EcoRI fragment of the PCR product was 
ligated into a pET17b plasmid (Novagen). The pET17b_MASP-
1-SP construct was transformed into Escherichia coli BL21 (DE3) 
pLysS host strain (Novagen) and the clones were selected in pres-
ence of ampicillin and chloramphenicol (SERVA). The expressed 
MASP-1-SP formed inclusion bodies; the pellet was collected and 
solubilized as described (40). The solubilized protein was added 
at 100 mg/L final concentration into refolding buffer containing 
50 mM Tris, 0.5 M arginine, 0.5 M NaCl, 5 mM EDTA, 6 mM 
glutathione, 4 mM oxidized glutathione, pH 8.0. The refolding 
solution was incubated at 4°C for 2–4 weeks then dialyzed against 
10 mM Na2HPO4, 0.5 mM EDTA, pH 6.8 buffer, and filtrated on 
0.45 µm cellulose-acetate membrane (Sartorius Stedim biotech). 
MASP-1-SP was loaded to a 26-mm ×  100-mm SP Sepharose 
High Performance (GE Healthcare) column equilibrated with 
10 mM Na-phosphate, pH 6.8 and eluted with a 0–200 mM NaCl 
linear gradient in the same buffer. Selected fractions were com-
bined and diluted 10-fold in 10 mM Tris, pH 8.2. The sample was 
applied to a 16-mm × 100-mm YMC BioPro Q30 (YMC Europe) 
column equilibrated with the same buffer, and eluted with a 
0–300  mM NaCl linear gradient. Several MASP-1-SP batches 
were pooled, dialyzed against 10 mM Na2HPO4, 150 mM NaCl, 
pH 7.4, concentrated to 1 mg/ml using spin concentrators, then 
passed through sterile syringe filter units.
Two rabbits were immunized by subcutaneous injections of 
MASP-1-SP. The first dose was 0.4 mg MASP-1-SP with Freund’s 
complete adjuvant. After 4 weeks, the injections were repeated 
four times, once in every fortnight with 0.2 mg MASP-1-SP in 
Freund’s incomplete adjuvant. Preimmune blood was withdrawn 
before the treatment and test blood samples were withdrawn a 
week after every boost from ear vein and finally the rabbits were 
bled after sixteen weeks. Sera were obtained by coagulation and 
centrifugation of the blood samples.
A two-step affinity chromatography purification method was 
used to obtain MASP-1-SP-specific antibodies from the pooled 
antiserum of two rabbits. Whole IgG was purified from the 
10-fold diluted immunsera using a 10  mm ×  100  mm Protein 
A (MabSelect SuRe, GE Healthcare) column. The sample was 
loaded in 10  mM Na2HPO4, 1  M NaCl, 1  mM EDTA, pH 7.0 
buffer, then eluted with a linear pH gradient ending in 100 mM 
citrate, pH 3.0. The immunoglobulin fractions were combined and 
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neutralized with 1 M Tris base, then further purified on MASP-
1cf (R448Q)-Sepharose resin. To produce the resin, 1 ml rehy-
drated CNBr-Activated Sepharose 4 Fast Flow (GE Healthcare) 
resin was reacted with 6 mg MASP-1cf (R448Q) according to the 
manufacturers protocol. The suggested final washes with solu-
tions of alternating pH were omitted. The pooled IgG fraction was 
twofold diluted with 20 mM Tris, 150 mM NaCl, 0.3% Tween-
20, pH 7.5 buffer and applied to a 5  mm ×  50  mm MASP-1cf 
(R448Q)-Sepharose column. Two overlapping populations of 
anti-MASP-1-SP antibodies, weakly and strongly binding, were 
eluted with linear pH gradient ending in 100 mM citrate, pH 3.0. 
The fractions were neutralized with 1 M Tris base and treated with 
0.02% NaN3 as preservative. Part of the strongly binding popula-
tion of anti-MASP-1-SP antibodies was concentrated to 1 mg/ml 
and conjugated with alkaline phosphatase enzyme (AP). The 
conjugation was performed by Alkaline Phosphatase Labeling 
Kit-NH2 (Abnova) using the manufacturers protocol.
MasP Purification from eDTa Plasma  
on MBl-sepharose
Mannose-binding lectin-Sepharose had been previously used by 
others to purify recombinant MASPs (45, 46). We modified this 
method to purify MASPs (and MAPs) from human EDTA plasma. 
Recombinant human MBL was dialyzed excessively against cou-
pling buffer (100  mM NaHCO3, 500  mM NaCl, pH 8.3), then 
concentrated to 4.75 mg/ml with 10 kDa cutoff concentrator. The 
concentration of rMBL was calculated based on the extinction 
coefficient of ε280 = 18,365 M–1 cm–1 and a molecular mass of a 
polypeptide of 24.0 kDa (not accounting for glycosylation).
Half a gram of CNBr-Activated Sepharose 4 Fast Flow resin 
was washed with 50  ml 1  mM HCl solution, then with sterile 
water, and finally equilibrated with coupling buffer. The resin 
was mixed with 2.1 ml 4.75 mg/ml rMBL and the mixture was 
rotated gently for 4 h at room temperature, and subsequently the 
beads were washed with 10  ml coupling buffer. After coupling 
the resin was washed with 5  ml 100  mM Tris (pH 8.0) buffer, 
then incubated for overnight with 8 ml of the same buffer at 4°C, 
then washed with 150 mM NaCl, 50 mM Tris, 10 mM CaCl2 (pH 
7.5) buffer and stored in the same buffer containing 0.02% NaN3. 
The coupling efficiency was about 2.5 mg rMBL per ml wet resin.
Plasma, 5  ml, containing about 10  mM EDTA (pool of 10 
donors or individual) was thawed at room temperature, and 
then was immediately mixed with 65 µl inhibitor stock solution 
[10 mM NPGB, 100 mM Pefabloc in anhydrous DMF (Merck)]. 
NaCl, 1.25 ml of 5 M, and 315 µl of 1 M Tris (pH 8.0) solutions 
were added to plasma containing the inhibitors, then supple-
mented with 100  µl of MBL-Sepharose resin. The mixture was 
rotated for 30 min at 0–8°C, then further 65 µl inhibitor stock 
solution was added. After twofold dilution with ice-cold sterile 
water, 85  µl of 2  M CaCl2 (12.5  mM final) was added, then it 
was rotated for 30 min at 4°C. Further steps were performed at 
room temperature however using ice-chilled buffers. The mixture 
containing the resin was loaded to a Poly-Prep Chromatography 
column (Bio-Rad, catalog number: 731-1550). The flow-through 
was discarded, the resin was washed with 500 µl ice-cold 50 mM 
Tris, 150 mM NaCl, 10 mM CaCl2, 0.1 mM NPGB, 1 mM Pefabloc 
(pH 7.5) buffer, then with 200 µl of ice-cold 50 mM Tris, 150 mM 
NaCl, 10  mM EDTA, 0.1  mM NPGB, 1  mM Pefabloc, pH 7.5 
buffer. After the washing steps an end cap was applied to column, 
and the resin was incubated with 150 µl elution buffer (50 mM 
Tris, 1 M NaCl, 20 mM EDTA, 0.1 mM NPGB, 1 mM Pefabloc, 
pH 8.0) for 5 min. Following incubation the end cap was removed 
and the eluate was collected, then another 150 µl of elution buffer 
was applied to column. The two eluted fractions were combined 
and after twofold dilution with ice-cold sterile water, the sample 
was mixed with 1/3 volume of 4× SDS-PAGE sample buffer then 
heated for 2 min at 95°C.
In order to produce samples without inhibitors, the same 
experiment was performed, but the last washing and the elution 
buffers did not contain NPGB and Pefabloc. After elution and 
dilution the mixture was incubated with MASP-1cf at 215  nM 
final concentration at 37°C, and aliquots were removed at 1.5 and 
5 h. The reaction was stopped by adding 1/3 volume of 4× SDS-
PAGE sample buffer and heating for 2 min at 95°C.
Western Blot analysis
Proteins in the samples were separated by SDS-PAGE under 
both reducing and non-reducing conditions. Stacking gels 
(125 mM Tris, pH 6.8) contained 5%, separating gels (750 mM 
Tris, pH 8.8) contained 12.5% acrylamide-bisacrylamide (37.5:1) 
solution, separation was performed at a constant voltage of 180 V 
in running buffer (25 mM Tris, 192 mM glycine, 0.1% w/v SDS, 
pH 8.3). Proteins were transferred to nitrocellulose membranes 
(Bio-Rad) in 25 mM Tris, 192 mM glycine, 20% v/v methanol, pH 
8.4 transfer buffer. Blotting was performed at a constant current 
of 120  mA for 60  min. After blocking for 1  h in 20  mM Tris, 
200  mM NaCl, 0.02% w/v NaN3, 5% w/v nonfat dry milk, pH 
7.2 blotting buffer, membranes were incubated overnight at room 
temperature with MASP-1-SP-AP antibody or MASP-3 mono-
clonal antibody in the same buffer at 1 or 2 µg/ml, respectively. 
Membranes blotted with the MASP-3 antibody were washed 
(20 mM Tris, 200 mM NaCl, 0.02% w/v NaN3, 0.3% v/v Tween-20, 
pH 7.2) for 30 min, then incubated for 1 h at room temperature 
with alkaline phosphatase conjugated goat anti-mouse antibody 
at 2,000-fold dilution in blotting buffer. After washing for 45 min, 
membranes were visualized with NBT/BCIP solution (5  mM 
MgCl2, 100 mM Tris, 400 mg/l NBT, 200 mg/l BCIP, pH 9.0). Blots 
were scanned with an Epson Perfection 4490 scanner in 16-bit 
grayscale reflective mode. Densitometric analysis of the Western 
blots was performed using the Quantity One software (Bio-Rad).
Determination of the MasP-3cf activation 
rate constants by Various Proteases
Zymogen MASP-3cf at a final concentration of 2 µM (96 µg/ml) 
in 140 mM NaCl, 10 mM HEPES, pH 7.4, 0.1 mM EDTA buffer 
was incubated at 37°C alone (negative control), or in the pres-
ence of various proteases. The final concentrations of the tested 
proteases and the incubation times were as follows. Active 
MASP-1cf had been used previously at 100 nM (4.6 µg/ml), and 
samples were removed periodically for up to 5 h (11). Zymogen 
R448Q MASP-1cf was used at 1  µM (46  µg/ml), and samples 
were removed periodically for up to 13 days (the reaction was 
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nearly complete at 6 days). Active MASP-2cf was used at 91 nM 
(3.9  µg/ml), and samples were removed periodically for up to 
3 h, and a final overnight sample was also collected. Zymogen 
R444Q MASP-2cf was used at 1 µM, and samples were removed 
periodically for up to 6 days (no cleavage was detected). Active 
MASP-3cf (autocatalytic cleavage) was used at 500  nM, and 
samples were removed periodically for up to 5 days (no appar-
ent increase in the amount of active MASP-3cf was detected). 
Zymogen MASP-3cf (self cleavage) as stated above was used at 
2 µM (96 µg/ml), and samples were removed periodically for up 
to 6 days (no cleavage was detected). Active FD was used at 1 µM, 
and samples were removed periodically for up to 4 h (no cleavage 
was detected).
Samples were analyzed by SDS-PAGE under reducing condi-
tions, followed by Coomassie Brilliant Blue G staining. Gels 
were scanned with an Epson Perfection 4490 scanner in 16-bit 
grayscale transparent mode. After scanning the intensities of the 
uncleaved substrate (zymogen MASP-3cf, 48  kDa) bands were 
quantified by densitometry using the BioRad Quantity One soft-
ware. The intensities of the product (active MASP-3cf B chain, 
31 kDa) bands were quantified in a similar fashion.
Substrate consumption was fitted using the IS = IB + Io × exp-
(−kobs  ×  t) equation, where IS stands for the intensity of the 
substrate band, Io is the intensity of the substrate band at the zero 
time point, and IB is the background intensity. When the substrate 
band overlapped with the enzyme band then the following equa-
tion was used instead: IP = IB + I∞ × [1 − exp(−kobs × t)], where IP 
is the intensity of the product band, and I∞ is the intensity of the 
product band at the completion of the reaction. First the observed 
pseudo first-order rate constants (kobs) were determined, then the 
kobs/[E]T values were calculated, where [E]T is the total enzyme 
concentration. The kobs/[E]T value can be considered as an 
approximation of the catalytic efficiency (kcat/KM) according to 
the Michaelis–Menten kinetics if the substrate concentration is 
much less than the KM. The kobs/[E]T values can also be used in 
kinetic simulations as approximate second-order rate constants.
Kinetic simulations
The fluid-phase activation and inhibition of lectin pathway 
proteases were modeled by kinetic simulations of the reaction 
network involving the zymogen, active, and inhibited forms of 
proteases and their inhibitors. The synthesis and elimination 
of the species were also included, resulting in a network of 25 
reactions (with non-zero rate constants) between 10 species 
(Table S1 in Supplementary Material). The biochemical system 
simulator program COPASI version 4.19 (47) was used. Time 
course analysis was performed by solving the system of differ-
ential equations using the deterministic LSODA method (48).
resUlTs
isolation of a Mixture of MasPs  
from Blood
Recombinant human MBL was coupled to CNBr-Activated 
Sepharose as described in the Section “Materials and Methods.” 
Our goal was to determine the extent of MASP-3 activation 
under resting conditions. Thus, we purified a pool of MASPs 
from EDTA plasma, and in order to prevent further activation of 
zymogen MASP-3 by other proteases, we used inhibitors NPGB 
and Pefabloc during the whole process, and the purification was 
carried out at 0–8°C. We mixed MBL-Sepharose with plasma 
in a way that the estimated immobilized rMBL to plasma PRM 
ratio was about 3 to 1 by mass. At the first step in the presence 
of 1  M NaCl and 10  mM EDTA, the PRM-MASP complexes 
dissociated. Then the NaCl and EDTA concentrations were 
reduced by dilution and excess CaCl2 was added to initiate re-
association of complexes. MASPs are expected to bind preferably 
to MBL-Sepharose as a result of the 3 to 1, immobilized rMBL 
to soluble PRM ratio. After reassociation the resin was packed 
into a column, and it was washed with low salt buffers to remove 
unbound proteins. The final elution buffer contained 1 M NaCl 
and 20 mM EDTA, dissociating MASPs (and MAPs) from the 
immobilized rMBL (Figure 1).
The samples were analyzed by SDS-PAGE followed by Western 
blotting. For detection our polyclonal MASP-1-specific anti-
body, or a commercial monoclonal MASP-3-specific antibody 
was used. Under reducing conditions, these antibodies recognize 
only the B-chain of active MASPs.
In order to identify the bands corresponding to the active and 
the zymogen variants under non-reducing conditions, we also 
prepared samples containing neither NPGB nor Pefabloc. Only 
the last washing and the elution buffers lacked the inhibitors. 
The eluate was incubated with MASP-1cf, and samples were 
withdrawn at 1.5 and 5  h. Upon this treatment under reduc-
ing conditions the bands corresponding to zymogen MASP-1 
and MASP-3 disappeared, and only the B-chains are seen, as 
expected. Under non-reducing conditions upon addition of 
MASP-1cf, the faster migrating bands disappeared, and only the 
slower migrating bands remained. Hence, the faster migrating 
band corresponds to the zymogen form, and the slower migrat-
ing band corresponds to the active form using non-reduced 
samples under our SDS-PAGE conditions (Figure 2).
MasP-3 is Mostly active, Whereas all 
MasP-1 is Zymogenic in the same 
isolates
During the isolation, we used NPGB and Pefabloc SC to pre-
vent activation of zymogen MASP-3 by any protease. Under 
non-reducing conditions zymogen and active MASP-3 are well 
separated by SDS-PAGE, on the other hand the mobilities of 
the two forms are only slightly different, which is favorable for 
the quantification.
For the quantification of the two forms of plasma MASP-3, 
we had several reasonable assumptions as follows: (I) the 
MBL-Sepharose resin binds zymogen and active MASP-3 with 
the same affinity, and no further activation occurs during the 
isolation; (II) the transfer efficiencies during Western blotting 
are equivalent due to the small difference between the mobility 
of zymogen and active MASP-3 under non-reducing condi-
tions; and (III) the commercial monoclonal MASP-3-specific 
antibody recognizes both forms of MASP-3 with the same 
sensitivity.
FigUre 1 | Scheme for the purification of mannose-binding lectin (MBL)-associated serine protease (MASPs) from human plasma. Human EDTA plasma was  
mixed with recombinant human mannan-binding lectin (rMBL)–Sepharose in the presence of high salt (1 M NaCl) causing to dissociate MASP– pattern recognition 
molecule (PRM) complexes. The ionic strength was decreased by dilution and excess CaCl2 was added to allow complexes to reassociate. MASPs (blue) are 
distributed between the original PRMs (green) from blood and the immobilized MBL (red). Soluble PRMs and soluble complexes are removed during the  
wash step. After washing, MASPs bound to rMBL-Sepharose were eluted with a buffer containing EDTA and high salt.
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First, we measured the activation state of plasma MASP-1 in 
our isolates as a control. We found that all MASP-1 remained 
zymogenic during the preparation, proving that the lectin path-
way did not activate during the isolation (Figure 2A, lanes 1–2 
and 4–5). It is in agreement with previous articles showing that 
MASP-1 is found in the zymogen form in the circulation (49, 50).
In contrast, in the same isolates we detected both forms of 
MASP-3 (Figure 2B, lanes 1–2, 5–6). We performed additional 
FigUre 2 | Western blot detection of mannose-binding lectin (MBL)-associated serine protease (MASP)-1 and MASP-3 isolated from normal human plasma  
in the presence of inhibitors. A pool of MASPs was purified from human plasma as outlined in Figure 1 in the presence of Pefabloc and 4-nitrophenyl 
4′-guanidinobenzoate (NPGB) inhibitors. A sample was prepared in the same manner except that the inhibitors were omitted at the last elution step. Samples were 
analyzed by SDS-PAGE under reducing and non-reducing conditions followed by Western blotting and detected using a MASP-1- or a MASP-3-specific antibody. 
Both antibodies were developed against the serine protease (SP) domain of the corresponding protein, hence they can detect the whole molecule, or the B chain  
of the active form. (a) MASP-1 was present as a zymogen in the isolated samples running at about 95 kDa under reducing conditions. When exogenous active 
recombinant MASP-1cf was added to the inhibitor-free sample, plasma MASP-1 is converted to the active form. The B chains of plasma MASP-1 and MASP-1cf 
both ran at about 28 kDa under reducing conditions. Under non-reducing conditions, activation of plasma MASP-1 produced a slower-migrating band compared  
to the zymogen form. MASP-1cf runs at about 45 kDa under non-reducing conditions. (B) MASP-3 was present both in the zymogen and the active forms in the 
isolated samples. The zymogen ran at about 100 kDa under reducing conditions and the (glycosylated) B-chain of the active form ran at about 40 kDa. Under 
non-reducing conditions active MASP-3 migrated slower than the zymogen form. The faint band, indicated by a question mark, running above the active form is 
probably due to non-specific binding. Addition of active recombinant MASP-1cf to the inhibitor-free sample caused the disappearance of the MASP-3 zymogen 
bands.
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three parallel isolations with pooled plasma, and each blot is 
shown in Figure 3A. Our results indicate that MASP-3 circulates 
mostly in the active form, and quantification revealed that the 
active–zymogen ratio was about 4 to 1 (Table 1).
low individual Variation of the active–
Zymogen ratio of MasP-3
In order to assess the individual variation of the active to zymo-
gen ratio for MASP-3, we examined EDTA plasma samples from 
seven healthy donors. The isolation procedure of MASPs from 
the individual plasma samples was the same as from the pooled 
samples. Each sample was analyzed three times by non-reducing 
SDS-PAGE followed by Western blot, then quantified. Figure 3B 
represents all individual samples together on the same blot 
membrane. In every sample MASP-3 was over 70% activated. 
While the total MASP-3 level can be quite different in each donor 
(36, 37), the active to zymogen ratio showed relatively low vari-
ation (Table 1).
In Vitro activation of MasP-3 by Various 
complement Proteases
Zymogen MASP-1 and MASP-2 are able to undergo autoactiva-
tion, and the active MASPs can activate their proenzymic coun-
terparts (41, 42), although for MASP-2 the autoactivation process 
is much slower (11). In contrast, Zundel et al. showed that neither 
the zymogen nor the active form of MASP-3 has a similar activity 
at all (46). We observed the same using the catalytic fragments of 
MASP-3 (Table 2).
It is now generally accepted that MASP-1, after autoactivation, 
activates zymogen MASP-2 (9–11). In vitro, active MASP-1 is able 
to activate MASP-3 as well (10, 21), and the cleavage rate has been 
determined using the catalytic fragments (11).
TaBle 2 | Rate constants for the activation of zymogen MASP-3cf.
enzyme kobs/[E]T (M–1 s–1)
Active MASP-1cf 1.2 ± 0.1 × 103a
Zymogen R448Q 
MASP-1cf
3.8 ± 0.9b
Active MASP-2cf 2.7 ± 0.5 × 103b
Zymogen R444Q 
MASP-2cf
~0
Active MASP-3cf ~0c,d
Zymogen MASP-3cf ~0d
Active FD ~0
The kobs/[E]T value can be considered as an estimate for the catalytic efficiency (kcat/KM). 
~0 indicates that no significant cleavage occurs even after several days.
aFrom Megyeri et al. (11).
bAverage ± SD, n = 4 is indicated.
cA very slow cleavage may occur corresponding to a kobs /[E]T << 1 M–1 s–1.
dOriginally observed by Zundel et al. (46) on full-length MASP-3 variants and confirmed 
by us using the catalytic fragments.
TaBle 1 | The fraction of active MASP-3 from pooled and individual plasma 
samples.
source sample Fraction of active MasP-3 (%)
Pooled plasma 78 ± 5
Individual plasma #1 76 ± 5
Individual plasma #2 79 ± 7
Individual plasma #3 86 ± 2
Individual plasma #4 83 ± 2
Individual plasma #5 85 ± 5
Individual plasma #6 76 ± 3
Individual plasma #7 79 ± 3
Average of the individual samples 81 ± 4a
Average ± SD from at least three parallels. The pooled plasma value represents 
average from three independent isolations, whereas the individual samples were run 
three times using the same isolate.
aAverage and deviation of the averages.
FigUre 3 | Western blot analysis of purified mannose-binding lectin 
(MBL)-associated serine protease (MASP) pools detected by a MASP-3-
specific antibody. MASPs were purified from human plasma as outlined in 
Figure 1 in the presence of Pefabloc and 4-nitrophenyl 4′-guanidinobenzoate 
(NPGB). Samples were analyzed by SDS-PAGE under non-reducing 
conditions followed by Western blotting and detection using a MASP-3-
specific antibody. The faint band running above the active form is probably 
due to non-specific binding of the antibody. Western blots were quantified as 
described in the Section “Materials and Methods” and the result are listed in 
Table 1. (a) The analysis of three parallel preparations starting from the same 
pool of human EDTA plasma. (B) The analysis of samples purified from the 
plasma of seven individuals. The full blots are provided as Figure S1 in 
Supplementary Material.
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For this study, we determined the missing rate constants of 
potential reactions that can produce active MASP-3 using the 
catalytic fragments of MASPs (Table 2; Figure 4). Out of curiosity 
we checked weather FD can activate MASP-3cf, but we could not 
detect any cleavage (data not shown, Table 2).
Similarly to active MASP-1cf, active MASP-2cf can also acti-
vate zymogen MASP-3cf at an approximately two-fold higher 
a rate (Figure  4A). It should be noted, however, that in the 
blood MASP-2 has a 20-fold lower concentration compared to 
MASP-1, hence its contribution to MASP-3 activation is likely 
to be much less than that of MASP-1 in vivo. Zymogen MASP-
2cf R444Q had no MASP-3cf cleaving activity at all (data not 
shown, Table 2). Interestingly the stable zymogen R448Q vari-
ant of MASP-1cf was also capable to activate MASP-3cf with a 
300-fold lower rate compared to the active enzyme (Figure 4B). 
Although this reaction is rather slow, it might have a signifi-
cance as the major variant of MASP-1 in resting blood is the 
zymogen form.
At the same time, zymogen MASP-3cf, when incubated alone, 
did not show any sign of activation upon prolonged incubation 
(Figure 4C), demonstrating that it does not autoactivate, and it is 
not contaminated by any external activating proteases. Also, no 
significant cleavage of zymogen MASP-3cf by active MASP-3cf 
was observed (data not shown, Table 2).
In Silico Modeling of the Fluid Phase Basal 
activation of lectin Pathway Proteases
We have determined previously (11, 12, 51) and for this study 
(Table  2) essentially all the possible activation rate constants 
between lectin pathway proteases using the catalytic fragments. 
These reactions include zymogen autoactivation, cross-activation 
between the zymogen forms, autocatalytic activation, and cross-
activation of a zymogen by another active MASP. Altogether 
there are 3 × 3 × 2 = 18 possible reactions, however “only” 10 
have non-zero rate constants and “only” 9 have a significant 
value (Table S1 in Supplementary Material). Activated MASP-1 
and MASP-2 are constantly inactivated by C1 inhibitor and 
antithrombin (12, 51). These reactions were also added to the 
reaction network (Table S1 in Supplementary Material). C1 
inhibitor might reversibly inhibit zymogen MASP-1 and MASP-2 
(42), however this possible effect was not included into the model, 
because no quantitative data are available for these interactions. 
Proteins are continuously synthesized and eliminated from the 
circulation. There are no data for human MASPs in this regard, 
however in mice the half life of MASP-1 and MASP-3 is about 
1.5 h (52). In our model, we used 6 h (arbitrarily) for all MASPs 
as humans have slower metabolism. This value corresponds to 
a 3.31 × 10−5 s−1 first order elimination rate constant. The same 
value was used for all forms of MASPs including the serpin inhib-
ited forms. This is a valid assumption as it was shown for C1s 
and C1s-C1 inhibitor complex in guinea pig (53). Synthesis rates 
(Table S1 in Supplementary Material) were calculated from the 
elimination rate constants and the measured steady-state plasma 
concentrations of MASPs (39).
Including the 10 activation, 4 inactivation, 3 synthesis, and 
8 elimination reactions a network of 25 reactions was set up. 
FigUre 4 | Activation of zymogen mannose-binding lectin (MBL)-associated serine protease (MASP)-3cf. Zymogen MASP-3cf at 2 µM was incubated with active 
MASP-2cf, or zymogen R448Q MASP-1cf, or alone. Aliquots were removed periodically at time points as indicated. Samples were analyzed by SDS-PAGE under 
reducing conditions. Molecular weights of the marker proteins in kDa are indicated. Zymogen MASP-3cf runs at about 48 kDa, while the active form gives two 
bands at about 31 and 17 kDa. Representative gels are shown as examples. (a). Activation by 91 nM active MASP-2cf. The band corresponding to the B chain of 
MASP-2cf (about 27 kDa) is very faint due to its low concentration. Lane 2 had zymogen MASP-3cf (M3cf) alone. (B) Activation by 1 µM zymogen R448Q 
MASP-1cf. The band of zymogen R448Q MASP-1cf (about 46 kDa) comigrated wit that of zymogen MASP-3cf. Quantification was carried out as described in the 
Section “Materials and Methods” and the determined rate constant are listed in Table 2. (c) Zymogen MASP-3cf alone is shown as a control demonstrating that it 
does not autoactivate or cleaved by any potential contaminant upon prolonged incubation.
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Starting with zero MASP concentrations, and assuming that 
MASPs are synthesized as proenzymes, simulations were run 
until steady-state concentrations were obtained. Simulation 1 
was run using the measured activation rate constants (Figure 5 
upper panels). According to simulation 1, only very little active 
MASP-3 is attained at steady-state (Table 3), which is not in line 
with our data. However, the simulation is in line with the obser-
vations that MASP-1 and MASP-2 circulate mostly as zymogens 
TaBle 3 | Distribution of zymogen, active, and serpin-inhibited forms of MASP 
molecules in the steady-state from kinetic simulations.
Molecule Variant Fraction (%)
simulation 1 simulation 2
MASP-1 Zymogen 55.7 55.7
Active 0.016 0.016
Inhibited 44.3 44.3
MASP-2 Zymogen 66.3 66.2
Active 0.00042 0.00042
Inhibited 33.7 33.8
MASP-3 Zymogen 99.3 43.8
Active 0.68 56.2
Simulation 1 was performed with measured rate constants. For simulation 2, the rate 
constant of MASP-3 activation by zymogen MASP-1 was increased by a factor of 200.
FigUre 5 | Kinetic simulations of the activation of lectin pathway proteases. Time courses of the concentrations of zymogen (zym), active (act), and combined 
C1-inhibitor and antithrombin bound (inh) forms of MASP proteases from kinetic simulations are shown starting with zero levels of mannose-binding lectin 
(MBL)-associated serine protease (MASPs). Simulation 1 was performed with measured rate constants. For Simulation 2, the rate constant of the activation of 
MASP-3 by zymogen MASP-1 was increased by a factor of 200. The full set of kinetic parameters is found in Table S1 in Supplementary Material. The reaction set is 
depicted in Figure 6 within the boxed area. Steady-state distributions are shown in Table 3.
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would correspond to a much faster reaction than that between 
isolated molecules. To account for this scenario the rate constant 
of MASP-3 activation by zymogen MASP-1 was increased arbi-
trarily by a factor of 200 (Simulation 2, Figure 5 lower panels). By 
this single modification, the active MASP-3 steady-state fraction 
increased to over 50% (Table 3), which is more in line with the 
observed >70% value. Values for MASP-1 and MASP-2 variants 
remained essentially the same. Of course this scenario raises 
several questions, which are discussed later.
comparison of the activation loop 
sequences of MasPs, c1r, and c1s
The activation loop of MASP-3 has an unusual sequence in 
comparison with those of MASP-1, MASP-2, C1r, and C1s 
(Table 4). The activation site is a R-I bond, which is the same in 
all the listed proteases. However, in MASP-3 the P1 Arg residue 
is preceded by a Lys residue, giving rise to a paired basic (KR) 
motif preceding the activation site. This motif coincides with the 
recognition motif of basic amino acid-specific proprotein con-
vertases, which is (K/R) − (X)n − (K/R)↓, where n = 0, 2, 4, or 6 
and X is any amino acid (56). Most often the cleavage site is after 
consecutive basic residues. There are of course other segments in 
the listed proteases, where a similar motif can be found, however 
the activation site of MASP-3 is exposed and hence suitable for 
(49), and some of them circulate as serpin-inhibited complexes 
(54, 55). It must be noted that our simulation cannot predict 
the precise ratios of the different MASP forms, because several 
simplifications were used, however, it is suitable to predict the 
general trends.
If we assume that a fraction of MASP-1 and MASP-3 reside 
on the same complexes and efficient intracomplex activation 
between zymogen MASP-1 and zymogen MASP-3 occurs, this 
TaBle 4 | P6-P6′ sequences of MASPs, C1r, and C1s.
Protease P6 P5 P4 P3 P2 P1 P1′ P2′ P3′ P4′ P5′ P6′
MASP-1 R K L M A r i F N G R P
MASP-2 R T T G G r i Y G G Q K
MASP-3 P S L V K r i I G G R N
C1r V E Q R Q r i I G G Q K
C1s F E E K Q r i I G G S D
Bold highlights the scissile R-I bond, whereas the potential recognition site (KR) for 
proprotein convertases is underlined.
FigUre 6 | Possible mechanisms of mannose-binding lectin (MBL)-
associated serine protease (MASP)-3 activation. The boxed part depicts 
activation and inactivation steps involving only lectin pathway proteases. 
Three forms of MASP-1 (zM1 for zymogen MASP-1, aM1 for active MASP-1, 
and iM1 for serpin-inhibited MASP-1), three forms of MASP-2 (zM2 for 
zymogen MASP-2, aM2 for active MASP-2, and iM2 for serpin-inhibited 
MASP-2), and two forms of MASP-3 (zM3 for zymogen MASP-3 and aM3 for 
active MASP-3) are shown as separate variants. Red arrows pointing from 
the enzyme to the substrate represent previously established activation 
reactions involving MASP-1 and MASP-2. Pink arrows (pointing from the 
enzyme to the substrate) represent possible activation reactions producing 
active MASP-3. Cleavage of zymogen MASP-3 by zymogen MASP-1 is 
highlighted by thick pink arrow (again pointing from the enzyme to the 
substrate). Inhibition by serpins is indicated by blue T-shaped symbols. Black 
arrows simply indicate conversion.
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purified samples. For quantification, the non-reduced samples 
are more suitable, because the two chains of active MASP-3 are 
held together by a disulfide bond, hence the masses of the active 
and zymogen forms are virtually identical, and their mobilities 
in polyacrylamide gels are very similar, though still allow their 
separation.
Mannose-binding lectin-associated SP-1 was always proenzy-
mic, whereas MASP-3 was a mixture of active and zymogen in 
all tested samples with active MASP-3 being the dominant form. 
On average, we found that MASP-3 was about 80% active, and 
in individual samples it was always more than 70% active, dis-
playing little individual variation. Using another technique, i.e., 
using anti-MASP-3 to pull out MASP-3, using different enzyme 
inhibitors and using different anti-MASP-3 antibodies on the 
Western blot also leads to the finding that a high proportion of 
the MASP-3 is found as activated MASP-3 (25).
We and others have postulated before that active MASP-1 
and MASP-2 is capable of activating MASP-3 (10, 11, 21). The 
rate constant for active MASP-1cf was measured previously (11), 
and here we also measured the activation rate constant for active 
MASP-2cf, which activates MASP-3cf about twice as fast as active 
MASP-1cf. It occurred to us that FD might reciprocally activate 
MASP-3, however, FD did not cleave zymogen MASP-3cf, neither 
did zymogen R444Q MASP-2cf. The zymogen MASP-1cf (R448Q 
variant) activated MASP-3cf slowly, but the rate constant was 
about 300-fold lower than that for active MASP-1cf.
Isolated full-length recombinant human MASP-3 does not 
autoactivate (46), neither does the catalytic fragment as previ-
ously shown (57) and unambiguously proved here using highly 
purified MASP-3cf. It is notable that recombinant MASP-3 can 
undergo slow activation upon prolonged storage. Zundel et  al. 
(46) observed this cleavage with the wild-type and the S645A 
(precursor numbering S664A) inactive variant of MASP-3 as 
well, and concluded that the observed activation is due to cleav-
age by a contaminating protease from the cell culture superna-
tant. Similar observations were made by Pihl et  al. (25). These 
observations indicate that the scissile R-I (449–450 precursor 
numbering) bond is sensitive to proteolysis by other proteases 
in general. Iwaki et al. (21) detected activation of recombinant 
mouse MASP-3 (also produced as proenzyme) in complex with 
MBL-A on Staphylococcus aureus. The authors postulated it as 
self-activation, but it is possible that a protease from S. aureus 
activated MASP-3. No activation was observed on uncomplexed 
MASP-3, MASP-3 in complex with other PRMs, or when other 
activators like mannan were used (21). In all, data in the literature 
with full-length dimeric MASP-3 and our observations with 
monomeric catalytic fragments indicate that MASP-3 does not 
autoactivate in general, and most importantly no autoactivation 
of MASP-3 was observed in the fluid phase.
It is enigmatic that MASP-3, which does not autoactivate, 
is present mostly in the active form in the circulation, whereas 
MASP-1, which has a potent autoactivation capacity, is proenzy-
mic. MASP-3 must be activated obviously by another protease, or 
proteases. Its activator may be another lectin pathway protease, or 
a yet unidentified protease in the blood, or possibly it is activated 
before secretion within the cells (Figure 6). In order to assess 
the first possibility, we set up a kinetic model for the fluid-phase 
such cleavage. The possibility of MASP-3 activation by proprotein 
convertases is also discussed later.
DiscUssiOn
Our previous studies revealed that active MASP-3 is the exclusive 
pro-FD activator in resting human blood (22, 23). This implied 
that active MASP-3 must be present in the blood, even without 
ongoing complement activation above the baseline level. We 
decided to confirm this assumption by a different approach, and 
to quantify the extent of MASP-3 activation, i.e., the active to 
zymogen ratio.
Initially, we attempted to detect MASP-3 directly in plasma 
samples, but the available antibodies were not suitable for this 
purpose because of the very high background. Therefore, we 
decided to enrich our samples for MASP-3. A mixture of MASPs 
and MAps was purified from EDTA plasma using MBL-Sepharose 
as described in the presence of broad specificity SP inhibitors in 
order to avoid any activation during the isolation. We detected 
MASP-3, and as a control MASP-1, by Western blotting in the 
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basal level activation of lectin pathway proteases using available 
and newly determined kinetic constants.
Previously, we have determined the rate constants for all 
possible activation steps involving MASP-1 and MASP-2 using 
the catalytic fragments (11). In this study, we added the missing 
rate constant (see above) for reactions producing active MASP-3. 
MASP-1 and MASP-2 are known to be inhibited by C1 inhibi-
tor and antithrombin (4, 58, 59), while MASP-3 is not (46, 60). 
Rate constants for the inactivation reactions had been previously 
determined (12, 51) and they were included into the model. 
Estimated elimination and synthesis rates were also included.
Running the simulation with the determined rate constant 
does not explain the observed phenomenon, i.e., that MASP-3 
is present mostly in the active form. It must be noted, however, 
that our kinetic model can adequately describe intermolecular 
reactions, but it is less suitable to describe intramolecular (intra-
complex) cleavage reactions.
We have attempted to modify the kinetic parameters to account 
for a potentially more efficient intramolecular (intracomplex) 
activation. By changing just one parameter—the activation reac-
tion of MASP-3 by zymogen MASP-1 was arbitrarily increased 
by 200-fold—the output became similar to the observed facts 
that MASP-2 and MASP-1 are proenzymic, and MASP-3 is 
extensively activated. Moreover, the presence of serpin-inhibited 
MASP-1 and MASP-2 complexes was observed in blood samples 
by others (54, 55) even in resting blood, and our simulations are 
completely in line with these observations.
It may occur to someone that if MASP-3 can be activated effi-
ciently by zymogen MASP-1 intramolecularly within a complex, 
why would not all zymogen MASP-1 autoactivate in a similar 
way, which is potentially a faster reaction. This question leads 
to a more general problem, i.e., how the different lectin pathway 
complexes really look like, and how they are really activated. 
This is a difficult question, and several activation scenarios 
have been proposed (61–63). It is possible that MASP-3 is only 
activated on highly multimeric PRMs that can accommodate 
dimers of both MASP-1 and MASP-3.
There are alternative explanations to account for the presence 
of active MASP-3 in circulation. It was proposed earlier for FD 
(27) that it might be activated within the secretory pathway in 
mammalian cells. The N-terminal sequence of pro-FD, APPRGR↓, 
however does not match the general recognition sequence of 
basic amino acid-specific proprotein convertases, which is 
(K/R) − (X)n − (K/R)↓, where n = 0, 2, 4, or 6 (56). In contrast, 
MASP-3 contains a paired basic residue motif at the activation 
site (SLVKR↓I), which satisfies the above-mentioned criterion. 
The observation that recombinant MASP-3 was always expressed 
as a proenzyme (21, 37, 46) even in mammalian cells contradicts 
this hypothesis. Therefore, if MASP-3 is activated intracellularly, 
it must be cell-type specific. Supporting this hypothesis is that 
furin and PACE4 can activate MASP-3 in vitro (64).
In summary, we have demonstrated that MASP-3, just 
like FD, circulates preferably in the active form in resting 
human blood. It is now clear that activated MASP-3 keeps 
FD mostly activated in the circulation, even in the absence of 
any complement triggering factors. Both active MASP-1 and 
active MASP-2 are able to activate MASP-3 fairly well. This 
mechanism might be important during infections. However, 
both MASP-1 and -2 are present as proenzymes in resting 
blood. The enigma cannot be easily resolved, but the ability 
of zymogen MASP-1 to cleave zymogen MASP-3 may provide 
a solution. We set up a kinetic model for the activation of 
lectin pathway proteases, which, along with other activation 
scenarios for MASP-3, is summarized in Figure 6. Our kinetic 
model, which also includes inactivation by serpins, adequately 
explains why MASP-1 and MASP-2 are proenzymic, but it 
can explain extensive MASP-3 activation only if we assume 
efficient intracomplex activation by zymogen MASP-1. Our 
kinetic model provides a reasonable explanation, however, 
elucidating the physiological activation mechanism of MASP-3 
requires further experiments.
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